“showed a trend”

The blood routine, renal function and protein levels of the patients showed a trend of improvement for three consecutive days after surgery, ACTH and plasma total cortisol (PTC) decreased to normal, and thyroid hormones tended to normal.

A post-hoc analysis of a randomized control trial showed a trend towards improved outcomes with lower target glucose control compared with conventional control in patients with A1C < 5.0%, even though hypoglycemia was more prevalent (adjusted hazard ratio 0.60, 95% CI 0.35–1.01; P = 0.052).

Other osteogenesis-associated genes (ALP, OCN, and Col1a) were not significantly expressed on day 7; however, they showed a trend similar to that of Runx2 and osterix on day 14. 3.3 Ectopic osteogenesis in muscle pouch 3.3.1 X-ray and EDS spectrum analysis The results showed that images of implants in the T0 group were almost uncaptured at all time points, whereas the images of implants in groups T5, T6, T7, and T8 exhibited varying degrees of mineralization with increasing time ( Fig. 4 a).

They showed a trend toward reduction of MI, TLF, and stent thrombosis (ST) for patients treated with BP‐SES. 14 Zhu et al. considered six RCTs comparing BP‐SES with two different durable polymer stents for the meta‐analysis, in which a significantly reduced risk for MI in BP‐SES treated subjects was found. 15 As the majority of these analyses was performed at publication level, detailed analyses of different patient subgroups were not possible.

Out‐of‐hospital SE onset showed a trend toward a higher total number of BZD doses compared to in‐hospital onset, and this difference was more prominent with a longer time from seizure onset.

4.3 Exposure–response for safety While the exposure–unbound E2 relationship showed a trend of lower E2 with increasing vilaprisan exposure, the E2 concentrations mostly remained within the physiologic range for the follicular phase and E2 levels returned to baseline for all patients in both ASTEROID 1 8 and ASTEROID 2. 9 Although a decrease in E2 levels will contribute to ovulation inhibition and consequently to induction of amenorrhoea, 6 the potential effect of a decrease in E2 levels on long‐term safety is considered to be of higher clinical relevance.

While proportions of CD86 + regulatory T cells of CD4 + T cells showed a trend towards a significant increase over time, regulatory T cells did not show differences over time.

In the dulaglutide group, renal function not only remained stable but also showed a trend towards improvement despite the advanced CKD; however, in the liraglutide group, there was a trend towards worsening renal function.

ODQ pretreated efferent arterioles also showed a trend towards increased sensitivity to runcaciguat as compared with L‐NAME pretreated efferent arterioles, but the difference did not reach statistical significance (Figure 3f ).

Unfortunately, the small number of individuals in the population with a TG13T5 variant limited the number of homozygous individuals available for assessment, although these individuals showed a trend in enrichment similar to patients with CFvar/CFvar genotypes.

While not statistically significant, TNFα levels in female htau brainstem and prefrontal cortex showed a trend towards similar irisin‐related reductions (Figure 3B ).

Previous and recent multicenter, randomized controlled trials showed a trend towards reduced mortality in favor of V‐V ECMO over conventional treatment. 6 , 7 Furthermore, in a recently published meta‐analysis of these trials, 60‐day mortality was significantly lower in the V‐V ECMO group. 8 Although mortality rates in V‐V ECMO are lower compared with other ECMO modalities, a substantial quote of patients still die during hospital admittance. 9 According to the Extracorporeal Life Support Organization (ELSO), more than 75 000 ECMO runs for respiratory compromise have been performed in more than 450 centers (as of July 2021).

In general, during the entire drought period, S‐D showed a trend towards lower values than L‐D (Figure S4 ), but no statistical differences were observed at any date of measurement. 3.3 Rewatering period Since irrigation was re‐started at different times for L‐D and S‐D containers, we present the g s and A N data in parallel as days of rewatering (DOR) to permit a direct comparison between L and S (Figure 3 ).

However, this relationship is lost after 4 and 8 weeks of ET once haematocrit decreased, and total plasma free haptoglobin showed a trend to rise suggesting a marginal increased haemolysis consequent to ET.

30%; P =0.09), but it showed a trend toward a higher rate in vitamin E treatment [ 237 ].

In a separate metabolic phenotyping cohort, diet-induced-obese C57BL/6J wild-type mice treated with the danegaptide and mirabegron combination therapy daily for 9 days showed a trend towards serum glucose reduction.

Progression-free survival (PFS) under molecular therapy compared to progression-free survival under the prior treatment regimen was not statistically different but showed a trend in favor of the targeted therapy (Fig. 7 a).

Younger individuals (18–39 years) showed a trend toward higher frequencies of spike-specific CD4 + T cells at day 35 but similar frequencies with elderly patient groups at 6 months ( Figure S2 A).

In the ventral hippocampus of SERT −/− rats at the third week of life, SERT deficiency resulted in a significant decrease in γ2 subunit of GABA A receptor ( GABA A γ2 ) and glutamic acid decarboxylase 1 ( Gad67 ) mRNA levels, while vesicular-GABA transporter ( Vgat ) only showed a trend of decreasing but not statistically significant.

In addition, mRNA-vaccinated patients who were treated with thiopurines showed a trend towards lower antibody concentrations compared to patients who were not treated with thiopurines (geometric mean [95% confidence interval]: 4523 [3574-5724] vs . 5634 [4561-6958] AU/ml, P=0.182).

When compared to the RP240 model, the RP340 model showed a trend of improved correlation with the manual grading for the measurement of EZ width (correlation coefficient changed to 0.988 from 0.981), increased linear regression slope (changed to 0.951 from 0.930), and reduced CoR (changed to 0.582 mm from 0.728 mm).

Similar to the HCRU, the overall annual HCRU direct cost also showed a trend toward highest mean AD-related HCRU gross cost (per patient) among moderate-to-severe treated AD cohort (531.5 USD) followed by the mild-to-moderate treated AD cohort (378.4 USD) and lowest for the untreated AD cohort (144.0 USD).

r antagonists, renin–angiotensin–aldosterone system inhibitors and angiotensin receptor neprilysin inhibitor (ARNI) might be used for patients with mildly reduced left ventricular ejection fraction ( HFmrEF; 41–49%), but with a IIB class of recommendation.[ 1 ] Indeed, the PARAGON-HF trial recently showed a trend towards better outcomes in HFpEF patients treated with sacubitril/valsartan (an ARNI) compared to valsartan, especially in the lower end of the left ventricular ejection fraction (LVEF) spectrum, in women, in patients recently hospitalised for HF, and in those with higher high sensitivity troponin values at baseline.[ 3 – 7 ] However, while the Food and Drug Administration has approved sacubitril/valsartan use in patients with ‘below normal’ LVEF, the European Medicines Agency has not.

Both B.1.351 and B.1.617 LNP-mRNA groups showed a trend of higher binding and neutralizing titers than WT group.

Considering the muscle mass loss present in RA sarcopenia [ 10 ], DMARD treatment not only prevented this but also showed a trend of a slight gain of muscle mass in analyzed parameters.